Document Classification

Section Type: RESULTS

Text: Treatment with ramipril reduced the rates of death from cardiovascular causes (6. 1 percent, as compared with 8. 1 percent in the placebo group ; relative risk, 0. 74 ; P < 0. 001), myocardial infarction (9. 9 percent vs. 12. 3 percent ; relative risk, 0. 80 ; P < 0. 001), stroke (3. 4 percent vs. 4. 9 percent ; relative risk, 0. 68 ; P < 0. 001), death from any cause (10. 4 percent vs. 12. 2 percent ; relative risk, 0. 84 ; P = 0. 005), revascularization procedures (16. 3 percent vs. 18. 8 percent ; relative risk, 0. 85 ; P < 0. 001), cardiac arrest (0. 8 percent vs. 1. 3 percent ; relative risk, 0. 62 ; P = 0. 02), [corrected] heart failure (9. 1 percent vs. 11. 6 percent ; relative risk, 0. 77 ; P < 0. 001), and complications related to diabetes (6. 4 percent vs. 7. 6 percent ; relative risk, 0. 84 ; P = 0. 03).